Samir Shah is a Respiratory physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
123 Newton Sparta Rd
Newton, NJ 078602769
Telephone
973-579-6300Registry record last updated 6 Feb 2017.
Clinical trials
- Vialize Use for the Reduction of Vascular Groin Incisional Dehiscence and Infection
Sponsor: University of Florida
- Supplement to Hospital to Home Outcomes
Sponsor: Children's Hospital Medical Center, Cincinnati
- Hospital to Home Outcomes
Sponsor: Children's Hospital Medical Center, Cincinnati
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20251 payment
- Inspire Medical Systems, Inc.Program year20242 payments
- ACADIA Pharmaceuticals IncProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
58.6%Corticosteroid26.1%Trelegy Ellipta38%Breo Ellipta20%Breztri Aerosphere12%Arnuity Ellipta10%Fluticasone Propionate8%Symbicort4%Budesonide-Formoterol Fumarate4%Breyna2%Fluticasone-Vilanterol1%Fluticasone Propionate Hfa1%Part D<11 patientsLeukotriene Receptor Antagonist14.1%Montelukast Sodium100%Part D≥204 patients+ 5 more classes in this area
Cardiovascular
13.2%Statin5.1%Atorvastatin Calcium54%Simvastatin24%Rosuvastatin Calcium23%Part D≥32 patientsBeta blocker2.4%Carvedilol50%Metoprolol Succinate31%Metoprolol Tartrate19%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
11.7%Corticosteroid5.2%Prednisone100%Part D≥126 patientsProton pump inhibitor4.4%Pantoprazole Sodium52%Omeprazole35%Esomeprazole Magnesium14%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”